Health Technology

Kyowa Kirin Co., Ltd.

Business Summary

Kyowa Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. It handles the research, development, production, and sale of in vitro diagnostic reagents and ethical drugs concerning renal anemia, leukemia, cancer, allergies, and hypertension. It also produces and sells medical and industrial raw materials such as amino acids, nucleic acid-related compounds, and healthcare products. The company was founded by Benzaburo Kato on July 1, 1949 and is headquartered in Tokyo, Japan.

Financial Highlights

Dec 2022	JPY	USD
Revenue	398,371M	3,028.80M
Gross Profit	301,363M	2,291.25M
Operating income	82,375M	626.29M
Income before tax	63,249M	480.87M
Net income	53,573M	407.31M
EBITDA	100,851M	766.76M
Diluted EPS	99.65	0.75
Dividends Per Share	51	0.38
Total Assets	939,881M	7,123.27M
Total liabilities	177,055M	1,341.88M
Total equity	762,826M	5,781.39M
Operating cash flow	48,672M	370.05M
	Currency in JPY	Currency in USD

Historical Data

JPY | USD

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022
Revenue	271,510M	305,820M	318,352M	352,246M	398,371M
Gross Profit	188,834M	215,129M	227,827M	253,894M	301,363M
Operating income	50,403M	53,354M	55,419M	61,110M	82,375M
Income before tax	66,841M	44,492M	52,263M	55,475M	63,249M
Net income	49,230M	37,674M	47,027M	52,347M	53,573M
EBITDA	66,646M	72,151M	75,885M	80,608M	100,851M
Diluted EPS	99.29	43.12	87.49	97.38	99.65
Dividends Per Share	35	42	44	46	51
Total Assets	741,982M	784,453M	801,290M	921,872M	939,881M
Total liabilities	92,589M	106,203M	102,893M	184,710M	177,055M
Total equity	649,621M	678,250M	698,396M	737,162M	762,826M
Operating cash flow	56,181M	53,655M	39,502M	86,548M	48,672M

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022
Revenue	2,458.37M	2,805.40M	2,981.70M	3,205.93M	3,028.80M
Gross Profit	1,709.78M	1,973.46M	2,133.84M	2,310.79M	2,291.25M
Operating income	456.37M	489.43M	519.05M	556.18M	626.29M
Income before tax	605.20M	408.14M	489.49M	504.90M	480.87M
Net income	445.75M	345.59M	440.45M	476.43M	407.31M
EBITDA	603.44M	661.87M	710.74M	733.64M	766.76M
Diluted EPS	0.89	0.39	0.81	0.88	0.75
Dividends Per Share	0.31	0.38	0.41	0.41	0.38
Total Assets	6,762.81M	7,218.33M	7,761.05M	8,005.48M	7,123.27M
Total liabilities	843.90M	977.25M	996.59M	1,604.01M	1,341.88M
Total equity	5,920.98M	6,241.08M	6,764.45M	6,401.47M	5,781.39M
Operating cash flow	508.68M	492.19M	369.97M	787.70M	370.05M

Valuation Measures

Dec 2022
PER	30.29
ROA	5.75%
ROE	7.14%
Operating margin	20.67%
Profit margin	13.44%

Key executives

President, CEO & Representative Director: Masashi Miyamoto
Executive Officer, Manager-Accounting & Finance: Motohiko Kawaguchi
Executive Officer, GM-Research & Development: Mitsuo Satoh
Representative Director & Executive Vice President: Yutaka Osawa
Executive Officer & General Manager-Sales: Hiroshi Sugitani

Shareholders

Kirin Holdings Co., Ltd. (53.4%)
Nomura Asset Management Co., Ltd. (3.2%)
Daiwa Asset Management Co. Ltd. (1.6%)
Massachusetts Financial Services Co. (1.5%)
Nikko Asset Management Co., Ltd. (1.5%)
The Vanguard Group, Inc. (1.2%)
BlackRock Fund Advisors (0.9%)
Mitsubishi UFJ Kokusai Asset Management Co., Ltd. (0.8%)
Norges Bank Investment Management (0.7%)
Goldman Sachs Asset Management Co., Ltd. (Japan) (0.5%)

Contact Details

Website:http://www.kyowa-kirin.co.jp
Address: Otemachi Financial City Grand Cube, 1-9-2 Otemachi, Tokyo, 100-0004, Japan
Phone: +81.3.5205.7200

Related Companies

Kyowa Kirin Australia Pty Ltd.
Kyowa Kirin Pharma FZ LLC
Kyowa Kirin Malaysia Sdn. Bhd.
Kyowa Kirin Korea Co., Ltd.
Kyowa Kirin Pharma SRL
Kyowa Kirin Pharma sro
Kyowa Kirin Austria GmbH
Kyowa Kirin SARL
Kyowa Kirin AB
Kyowa Kirin Pharma BV
Kyowa Kirin Holdings BV
Kyowa Kirin Farmaceutica SL
Kyowa Kirin Ireland Ltd.
Kyowa Kirin Canada, Inc.
Kyowa Kirin Frontier Co., Ltd.
Kyowa Medical Promotion Co., Ltd.
Kyowa Kirin GmbH
Strakan International SARL
Kyowa Kirin Plus Co., Ltd.
Kyowa Hakko Bio Co. Ltd. (Beijing)
Kyowa Hakko Bio (Shanghai) Trading Co., Ltd.
Kyowa Hakko Bio (Shanghai) Trading Co. Ltd. /Beijing Branch/
Kyowa Hakko Bio Shanghai Trading Co. Ltd. /Guangzhou/
Kyowa Hakko Kirin (Hong Kong) Co. Ltd.
Kyowa Hakko Kirin (Taiwan) Co. Ltd.
Kyowa Hakko Kirin (Singapore) Pte Ltd.
Kyowa Hakko Kirin China Pharmaceutical Co., Ltd.
Kyowa Hakko Kirin (Thailand) Co. Ltd.
ProStrakan SRL
Kyowa Hakko Kirin America, Inc.

Competitors

JW Holdings Corporation
Genexine, Inc.
Tonix Pharmaceuticals Holding Corp.
4d Pharma PLC
Vaxxinity Inc Class A
Innate Pharma SA Class A
FibroGen, Inc.
Heron Therapeutics Inc
Tetralogic Pharmaceuticals Corporation
Citius Pharmaceuticals Inc
Ikena Oncology, Inc.
Seagen, Inc.
Connect Biopharma Holdings Ltd. Sponsored ADR
Springworks Therapeutics, Inc.
Prometheus Biosciences, Inc

Last Updated on 24 Mar, 2023